Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF MARCH 12, 2022 SAM #7407
SOLICITATION NOTICE

65 -- Purchase of Aptima HIV-1 Quant DX Kits

Notice Date

3/10/2022 8:31:02 AM
 

Notice Type

Presolicitation
 

NAICS

325413 — In-Vitro Diagnostic Substance Manufacturing
 

Contracting Office

CDC OFFICE OF ACQUISITION SERVICES ATLANTA GA 30333 USA
 

ZIP Code

30333
 

Solicitation Number

75D30122-Q-74551
 

Response Due

3/25/2022 2:00:00 PM
 

Point of Contact

Liubov Kriel, Phone: 7704882856
 

E-Mail Address

vyh1@cdc.gov
(vyh1@cdc.gov)
 

Description

The Center for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Division of HIV Prevention (DHP), Laboratory Branch (LB), intends to award a sole source purchase order to Gen-Probe Incorporated (�Hologic�), 250 Campus Dr, Marlborough, MA 01752 for the purchase of Aptima HIV-1 Quant DX kits. The statutory authority for this sole source acquisition is 41 U.S.C.1708 in accordance with FAR Part FAR 13.106-1(b)(1), only one source is reasonably available to satisfy the agency requirement. The NAICS code for this procurement is 325413, In-Vitro Diagnostic Substance Manufacturing. The purpose of this acquisition is to purchase HIV-1 Quant DX kits. This kit is the only FDA-approved assay available in the US that can be used for diagnosis and monitoring of HIV-1 infections. This kit is exclusively for use on the Hologic Panther platform that CDC has in the CLIA laboratory for patient reporting. The Division of HIV Prevention HIV Laboratory tests patient samples for HIV infection, which can only be done with reagent kits approved by the FDA and with the compatible instrument. Gen-Probe Incorporated is the only responsible source capable of meeting the Government�s requirement because they are the only vendor that can manufacture these kits. Kits from other manufacturers are not compatible and are not approved for use so cannot be considered. Thus, Gen-Probe Incorporated, the manufacturer of these kits, is the only company that can be used.� As a result of this synopsis, no competitive solicitation will be posted on sam.gov.� We will issue only one solicitation to Gen-Probe Incorporated. However, firms that believe they can meet these requirements are encouraged to identify themselves and give written notice by providing a capability statement to the Contracting Officer by March 25, 2022.� The Contracting Officer will not respond to verbal request. All requests must be in writing. A determination by the Government�not to�compete this proposed action will be based on responses to this notice and�are solely within the discretion of the Contracting Officer.� Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.� Inquiries shall be sent to Liubov Kriel by email at vyh1@cdc.gov and reference solicitation number 75D301-22-Q-74551 on the subject line.
 

Web Link

SAM.gov Permalink
(https://sam.gov/opp/e1a594ae912d4206ba12268774a579d9/view)
 

Place of Performance

Address: Marlborough, MA 01752, USA

Zip Code: 01752

Country: USA
 

Record

SN06263813-F 20220312/220310230110 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |